Study wrapper · #320
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
Editor's note
This is a narrative clinical review of sexual health after breast and gynecologic cancer, and bremelanotide appears only briefly among options mentioned for low desire. The authors state that bremelanotide and flibanserin have shown efficacy for low desire, but the review does not present cancer-survivor-specific trial data for the peptide — that is an extrapolation from its premenopausal-HSDD approval to a population it was not tested in. That gap matters: cancer survivors often have distinct hormonal, vascular, and psychological drivers of sexual dysfunction, and safety or benefit in this group cannot be assumed from general HSDD trials. The review's more concrete guidance concerns non-hormonal measures (moisturizers, lubricants, dilators, pelvic-floor therapy) and cautions against vaginal lasers and compounded hormones in these patients. Weight the bremelanotide content as a passing mention within a synthesis that applied no formal quality-grading tool, not as evidence of benefit in survivors.
Plain-language abstract
Sexual difficulties are common but often overlooked after breast and gynecologic cancer, including vaginal dryness, pain during sex, and reduced desire. The authors searched three databases for peer-reviewed studies from the past 30 years and grouped what they found by cancer type, treatment, and effect on sexual function. They report that many symptoms stem from a menopause-like state triggered by cancer therapy. For day-to-day relief, they describe non-hormonal steps such as avoiding irritants, using vaginal moisturizers and lubricants, dilators, and pelvic-floor therapy; local hormone options may suit some patients depending on whether their cancer is hormone-sensitive. For low sexual desire, they mention that the medications bremelanotide and flibanserin have shown benefit in studies — though those studies were not specifically in cancer survivors. They caution that vaginal lasers and compounded hormones can pose meaningful risks for these patients and should be avoided. The authors conclude that care should be individualized and involve gynecologic, psychological, and cancer specialists together. This is a review summarizing existing literature, not a new trial.